Nervgen Pharma (NGEN) Current Leases (2024 - 2025)
Nervgen Pharma's (NGEN) quarterly Current Leases came in at $6001.3 in Q4 2025, down 91.38% year-over-year from $69604.9 in Q4 2024, and down 91.38% quarter-over-quarter from $69604.9 in Q4 2024.
Powered by 
Analysis
Nervgen Pharma (NGEN) Current Leases (2024 - 2025) Analysis & Trends
Nervgen Pharma (NGEN) has reported Current Leases for 2 consecutive years, with $6001.3 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Current Leases fell 91.38% year-over-year to $6001.3 in Q4 2025; TTM through Dec 2025 was $6001.3, a 91.38% decrease from a year earlier, with the FY2025 full-year figure at $6001.3, down 91.55% from the prior year.
- Current Leases was $6001.3 for Q4 2025 at Nervgen Pharma, down from $69604.9 in the prior quarter.
- Over five years, Current Leases peaked at $69604.9 in Q4 2024 and troughed at $6001.3 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.70 Bn | 192.71 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.18 Bn | 177.00 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 720.00 Mn |
| 5 | Argenx Se | 60.60 Bn | 55.42 Bn | 1.37 Bn | 11.00 Mn |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.46 Bn | 30.15 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.10 Bn | 29.10 Bn | 1.16 Mn | 12.38 Mn |
| 10 | Nervgen Pharma | 152.98 Mn | 152.98 Mn | - | - |